Vericel (VCEL)
(Delayed Data from NSDQ)
$35.63 USD
+0.69 (1.97%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $35.64 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VCEL 35.63 +0.69(1.97%)
Will VCEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VCEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VCEL
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
VCEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for VCEL
Vericel (VCEL) Price Target Reduced Despite Solid Earnings
Vericel price target lowered by $3 at Canaccord, here's why
Canaccord Genuity Lowers Price Target on Vericel (VCEL) but Maintains 'Buy' Rating | VCEL Stock News
Vericel Corp (VCEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Decoding Vericel Corp (VCEL): A Strategic SWOT Insight